Oral Oncology
Volume 40, Issue 8 , Pages 761-772 , September 2004

Radioimmunodetection and radioimmunotherapy of head and neck cancer

  • Pontus K.E Börjesson

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    • ,
  • Ernst J Postema

      Affiliations

    • Department of Nuclear Medicine, University Medical Center Nijmegen, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands
    • ,
  • Remco de Bree

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    • ,
  • Jan C Roos

      Affiliations

    • Department of Nuclear Medicine, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    • ,
  • C.René Leemans

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    • ,
  • Kalevi J.A Kairemo

      Affiliations

    • Department of Clinical Physiology and Nuclear Medicine, Uppsala University Hospital, S-75185 Uppsala, Sweden
    • ,
  • Guus A.M.S van Dongen

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-444-0953; fax: +31-20-444-3688

Received 12 November 2003 ,Accepted 21 November 2003.

References 

  1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. New Engl. J. Med. 1993;328:184–194
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94:153–156
  3. Leemans CR, Tiwari R, Nauta JJP, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993;71:452–456
  4. Ali S, Tiwari RM, Snow GB. False-positive and false-negative neck nodes. Head Neck Surg. 1985;8:78–82
  5. van den Brekel MWM, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al.  Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177:379–384
  6. van den Brekel MWM, Castelijns JA, Croll GA, Stel HV, Valk J, van der Waal I, et al.  Magnetic resonance imaging vs palpation of cervical lymph node metastasis. Arch. Otolaryngol. Head Neck Surg. 1991;117:663–673
  7. van den Brekel MWM, Castelijns JA, Stel HV, Luth WJ, Valk J, van der Waal I, et al.  Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology. 1991;180:457–461
  8. Höft S, Muhle C, Brenner W, Sprenger E, Maune S. Fine-needle aspiration cytology of the sentinel lymph node in head and neck cancer. J. Nucl. Med. 2002;43:1585–1590
  9. Nieuwenhuis EJC, Castelijns JA, Pijpers R, van den Brekel MWM, Brakenhoff RH, van der Waal I, et al.  Wait-and-see policy for the N0 neck in early-stage oral and oropharyngeal squamous cell carcinoma using ultrasonography-guided cytology: is there a role for identification of the sentinel node?. Head Neck. 2002;24:282–289
  10. Koch WM, Choti MA, Civelek AC, Eisele DW, Saunders JR. Gamma probe-directed biopsy of the sentinel node in oral squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1998;124:455–459
  11. Shoaib T, Soutar DS, MacDonald DG, Camilleri IG, Dunaway DJ, Gray HW, et al.  The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically N0 neck. Cancer. 2001;91:2077–2083
  12. Pitman KT, Ferlito A, Devaney KO, Shara AR, Rinaldo A. Sentinel lymph node biopsy in head and neck cancer. Oral Oncol. 2003;39:343–349
  13. Civantos FJ, Gomez C, Duque C, Pedroso F, Goodwin WJ, Weed DT, et al.  Sentinel node biopsy in oral cavity cancer: correlation with PET scan and immunohistochemistry. Head Neck. 2003;25:1–9
  14. Nieuwenhuis EJC, Jaspars LH, Castelijns JA, Bakker B, Wishaupt RGA, Denkers F, et al.  Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates. Clin. Cancer Res. 2003;9:755–761
  15. Adams S, Baum RP, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur. J. Nucl. Med. 1998;25:1255–1260
  16. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch. Otolaryngol. Head Neck Surg. 1999;125:1322–1328
  17. Stokkel MPC, ten Broek FW, van Rijk PP. Preoperative assessment of cervical lymph nodes in head and neck cancer with fluorine-18 fluorodeoxyglucose using a dual-head coincidence camera: a pilot study. Eur. J. Nucl. Med. 1999;26:499–503
  18. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck. 2002;24:345–349
  19. Hyde NC, Prvulovich E, Newman L, Waddington WA, Visvikis D, Ell P. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol. 2003;39:350–360
  20. Postema EJ, Oyen WJG, Marres HAM, Merkx MAW, van den Hoogen FJA. The role of FDG-PET in the detection of lymph node metastases in patients with N0 oral cavity cancer. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(Suppl 2):S159
  21. van den Brekel MWM, van der Waal I, Meijer CJLM, Freeman JL, Castelijns JA, Snow GB. The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope. 1996;106:987–991
  22. Stuckensen T, Kovács AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J. Craniomaxillofac Surg. 2000;28:319–324
  23. Greven KM, Keyes JW, Williams DW, McGuirt WF, Joyce WT. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. 1999;86:114–118
  24. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 1992;33:1972–1980
  25. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J. Nucl. Med. 1996;37:441–446
  26. Dennington ML, Carter DR, Meyers AD. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope. 1980;90:196–201
  27. Zbären P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch. Otolaryngol. Head Neck Surg. 1987;113:762–764
  28. Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch. Otolaryngol. Head Neck Surg. 1993;119:65–68
  29. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stages III and IV head and neck cancer. Head Neck. 2001;23:1056–1060
  30. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BFAM, Vaalburg W, et al.  Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur. J. Nucl. Med. 2002;29:1024–1030
  31. Taneja C, Allen H, Koness RJ, Radie-Keane K, Wanebo HJ. Changing patterns of failure of head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2002;128:324–327
  32. Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin. Nucl. Med. 1997;27:10–29
  33. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, et al.  Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer. 1993;68:403–406
  34. Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, et al.  Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab′)2. J. Nucl. Med. 1996;37:1504–1510
  35. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al.  Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med. 1997;38:858–870
  36. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. 2002;13:609–614
  37. Kretzschmar T, von Rüden T. Antibody discovery: phage display. Curr. Opin. Biotechnol. 2002;13:598–602
  38. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 2002;13:593–597
  39. Hazra DK, Britton KE, Lahiri VL, Gupta AK, Khanna P, Saran S. Immunotechnological trends in radioimmunotargeting: from ‘magic bullet’ to ‘smart bomb’. Nucl. Med. Commun. 1995;16:66–75
  40. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750–4755
  41. Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, et al.  Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer. 2002;99:396–402
  42. Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, et al.  Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2003;52:576–582
  43. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 1994;12:1193–1203
  44. Hicklin DJ, Witte L, Zhu Z, Liao F, Wu Y, Li Y, et al.  Monoclonal antibody strategies to block angiogenesis. Drug Discovery Today. 2001;6:517–528
  45. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 2001;16:125–132
  46. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003;9:571–579
  47. Tranter RM, Fairweather DS, Bradwell AR, Dykes PW, Watson-James S, Chandler S. The detection of squamous cell tumours of the head and neck using radio-labelled antibodies. J. Laryngol. Otol. 1984;98:71–74
  48. Kairemo KJA, Hopsu EVM. Imaging of tumours in the parotid region with Indium-111-labeled monoclonal antibody reacting with carcinoembryonic antigen. Acta Oncol. 1990;29:825–830
  49. Kairemo KJA, Hopsu EVM. Imaging of pharyngeal and laryngeal carcinomas with indium-111-labeled monoclonal anti-CEA antibodies. Laryngoscope. 1990;100:1077–1082
  50. Timon CI, McShane D, Hamilton D, Walsh MA. Head and neck cancer localization with indium labelled carcinoembryonic antigen: a pilot project. J. Otolaryngol. 1991;20:283–287
  51. De Rossi G, Maurizi M, Almadori G, Di Giuda D, Paludetti G, Cadoni G, et al.  The contribution of immunoscintigraphy to the diagnosis of head and neck tumours. Nucl. Med. Commun. 1997;18:10–16
  52. Soo KC, Ward M, Roberts KR, Keeling F, Carter RL, McCready VR, et al.  Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head Neck Surg. 1987;9:349–352
  53. Baum RP, Adams S, Kiefer J, Niesen A, Knecht R, Howaldt HP, et al.  A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT. Acta Oncol. 1993;32:747–751
  54. Heissler E, Grunert B, Barzen G, Fritsche L, Hell B, Felix R, et al.  Radioimmunoscintigraphy of squamous cell carcinoma in the head and neck region. Int. J. Oral Maxillofac. Surg. 1994;23:149–152
  55. Adamietz IA, Baum RP, Schemman F, Niesen A, Knecht R, Saran F, et al.  Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT. J. Nucl. Med. 1996;37:1942–1946
  56. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GAMS. Clinical screening of monoclonal antibodies323/A3 (K931), cSF-25 (K984), and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl. Med. Commun. 1994;15:613–627
  57. de Bree R, Roos JC, Quak JJ, den Hollander W, van den Brekel MWM, van de Wal JE, et al.  Clinical imaging of head and neck cancer with 99mTc-labeled monoclonal antibody E48 IgG or F(ab′)2. J. Nucl. Med. 1994;35:775–783
  58. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GAMS. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res. 1995;1:591–598
  59. Stroomer JWG, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, et al.  Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 2000;6:3046–3055
  60. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, et al.  Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med. 2000;41:1999–2010
  61. Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Börjesson PKE, et al.  Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin. Cancer Res. 2002;8:3401–3406
  62. Börjesson PKE, Postema EJ, Roos JC, Colnot DR, Marres HAM, van Schie MH, et al.  Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2003;9:3961s–3972s
  63. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol. Immunother. 2003;52:342–346
  64. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73:787–793
  65. Brakenhoff RH, Gerretsen M, Knippels EMC, van Dijk M, van Essen H, Olde Weghuis D, et al.  The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell–cell adhesion. J. Cell Biol. 1995;129:1677–1689
  66. van Dongen GAMS, Leverstein H, Roos JC, Quak JJ, van den Brekel MWM, van Lingen A, et al.  Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab′)2. Cancer Res. 1992;52:2569–2574
  67. van Hal NL, van Dongen GAMS, Rood-Knippels EMC, van der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer. 1996;68:520–527
  68. de Bree R, Roos JC, Quak JJ, den Hollander W, Wilhelm AJ, van Lingen A, et al.  Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab′)2 in patients with head and neck cancer. Clin. Cancer Res. 1995;1:277–286
  69. de Bree R, Roos JC, Plaizier MA, Quak JJ, van Kamp GJ, den Hollander W, et al.  Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J. Cancer. 1997;75:1049–1060
  70. Wilson CB, Snook DE, Dhokia B, Taylor CV, Watson IA, Lammertsma AA, et al.  Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int. J. Cancer. 1991;47:344–347
  71. Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, et al.  PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med. 1992;33:2020–2023
  72. Kairemo KJ. Positron emission tomography of monoclonal antibodies. Acta Oncol. 1993;32:825–830
  73. Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O’Keefe GJ, et al  Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J. Nucl. Med. 2001;42:764–769
  74. Verel I, Visser GWM, Boerman OC, van Eerd JEM, Finn R, Boellaard R, et al.  Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm. 2003;18:655–661
  75. Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 2003;44:1271–1281
  76. Verel I, Visser GWM, Boellaard R, Boerman OC, van Eerd J, Snow GB, et al.  Zirconium-89 immuno-PET: scouting of yttrium-90-labeled monoclonal antibodies. J. Nucl. Med. 2003;44:1663–1670
  77. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–340
  78. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al.  High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer. 2002;94:1363–1372
  79. Paganelli G, Orecchia R, Jereczek-Fossa B, Grana C, Cremonesi M, de Braud F, et al.  Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur. J. Nucl. Med. 1998;25:1336–1339
  80. Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. 1995;55:1060–1069
  81. de Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MWM, Castelijns JA, et al.  The impact of tumour volume and other characteristics on uptake of radiolabeled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur. J. Nucl. Med. 1998;25:1562–1565
  82. van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GAMS. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int. J. Cancer. 1998;77:13–18
  83. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000;6:701–708
  84. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al.  Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002;8:3250–3258

PII: S1368-8375(03)00254-9

doi: 10.1016/j.oraloncology.2003.11.009

Oral Oncology
Volume 40, Issue 8 , Pages 761-772 , September 2004

Article Tools

* Image Usage & Resolution